Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP35m

    Last close

    GBP0.34

    ▲ 10.25 (44.09%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    VolitionRx

    MCap

    USD70m

    Last close

    USD0.85

    ▲ 0.25 (41.67%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Incannex Healthcare (NASDAQ: IXHL)

Last close As at 24/04/2024

USD0.97

▲ −0.11 (−10.19%)

Market capitalisation

62m

Latest Insights

View More

Healthcare | Update

Incannex Healthcare — Spotlight on Incannex’s progress in psychedelics

Healthcare | Flash note

Incannex Healthcare — On the road to psychotherapy clinics

Healthcare | Flash note

Incannex Healthcare — On to Phase II for IHL-675A

Healthcare | Flash note

Incannex Healthcare — A clinically active quarter
incannex07
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net cash (A$m)

29.6

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.0) (36.3) (76.2)
Relative (12.3) (38.0) (79.3)
52 week high/low US$4.0/US$0.8

Financials

Incannex, an Australian-based biotech, has several active studies investigating cannabinoid combinations for a range of conditions, but is also focused on assessing psilocybin for the treatment of generalized anxiety disorder (GAD). In the psychedelics space, Incannex’s ongoing Phase II trial (Psi-GAD) received an encouraging interim review in March 2023, and we see the completion of the study in Q4 CY23 as a significant catalyst. Incannex has also recently announced developments in its psychedelic clinics business through its subsidiary Clarion Clinics Group. In this note, we provide an overview of psychedelics as therapeutics, the GAD market, and Incannex’s position in the emerging field of psychedelic-based therapies. Our valuation for Incannex stands at US$750.7m or US$11.83 per ADR (vs US$745.8m or US$11.75 per ADR previously).

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.0 N/A (8.2) (0.83) N/A N/A
2022A 0.8 N/A (14.9) (1.25) N/A N/A
2023E 0.1 N/A (20.7) (1.43) N/A N/A
2024E 0.1 N/A (33.4) (2.10) N/A N/A

Research

Update

Healthcare

Incannex Healthcare — Expanding base with A$13m private placement

edison tv

Healthcare

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42
incannex07

Healthcare

Flash note

Incannex Healthcare — Progressing the opportunity in anxiety treatment

incannex07

Further insights

insight

Healthcare

Incannex’s US redomicile is now complete – what’s next?

insight

Healthcare

Incannex Healthcare: Is life better on Nasdaq?
Incannex mother and child

insight

Healthcare

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

Healthcare Week 2023
thumbnail_incannex

insight

Healthcare

Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42X

insight

Healthcare

Seven things every investor needs to know about Incannex Healthcare

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

thematic

Healthcare

Machine learning in drug development

thematic

Healthcare

Outlook for 2023: Biotechs remain central to novel drug development
Cancer cells

thematic

Healthcare

Oncology ABCs (part four): Blood cancers (AML) – notable innovations
cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

Edison healthcare quarterly: How to please some of the people some of the time